The following stories appear in full on Today's Vidyya Medical News Service Web site.
The first international guidelines for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease (COPD) currently the fourth leading cause of death in the US and worldwide were released yesterday by an international team of scientists from the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The GOLD Workshop Report, which provides evidence-based recommendations for the clinical management of COPD, is the first step in an international effort to boost awareness of COPD and improve the way it is treated. GOLD was created by the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health and the World Health Organization.
For more information: International Guidelines Released On Chronic Obstructive Lung Disease (COPD)
The GOLD Workshop Report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, presents a COPD management plan with four components: (1) Assess and Monitor Disease; (2) Reduce Risk Factors; (3) Manage Stable COPD; and (4) Manage Exacerbations. The Workshop Report is based on the best-validated current concepts of COPD pathogenesis and the available evidence on the most appropriate management and prevention strategies. It has been developed by individuals with expertise in COPD research and patient care and extensively reviewed by many experts and scientific societies. Prior to its release for publication, the Workshop Report was reviewed by the NHLBI and the WHO. This Executive Summary provides key information about COPD.
For more information: Executive Summary: Global Initiative For Chronic Obstructive Lung Disease
Health care professionals at more than 1200 sites stand ready to educate the public about signs and symptoms of alcohol problems during the third annual National Alcohol Screening Day (NASD) today, Thursday, 05 April 2001.
For more information: Prescribing Information: Lipitor (Artorvastatin ®)
The New England Journal of Medicine (NEJM) today published Phase I data regarding Glivec* [GLEE-vek] (formerly STI571), the oral investigational agent from Novartis Oncology for the treatment of patients with chronic myeloid leukemia (CML). Also featured in this issue of the NEJM is a case history of the treatment of a patient with a gastrointestinal stromal tumor (GIST). GISTs are solid tumors that express an activated protein shown to be inhibited by Glivec. The publication of these studies comes shortly after Novartis Oncology submitted applications with health authorities globally seeking marketing authorization for Glivec for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase after failure of interferon-alpha therapy.
For more information: New England Journal Of Medicine Releases Phase I Data On Investigational Anti-Cancer Therapy - Glivec
The number of confirmed cases in the outbreak of tuberculosis at a Leicestershire school has risen to 27. The outbreak is now the worst in the UK for many years.
For more information: Tuberculosis Outbreak Confirmed At UK School
Today's Vidyya articles are:
As always, we hope you enjoy the issue.